Skip to main content

Advertisement

SpringerLink
Log in

Neurosarcoidosis

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Neurosarcoidosis is an uncommon presentation of sarcoidosis. It is associated with significant morbidity and poor outcome. In the past decade, there has been significant progress in our understanding of the immunopathogenesis of the disease, but the etiology of this enigmatic condition still eludes us. Improved insight has paved the way for development of different treatment strategies against critical immunologic stages of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Burns TM: Neurosarcoidosis. Arch Neurol 2003, 60:1166–1168. This article is a detailed account of the history of sarcoidosis, in particular neurosarcoidosis.

    Article  PubMed  Google Scholar 

  2. HunninghakeGW, Costabel U, Ando M, et al.: ATS Statement on sarcoidosis. Am J Respir Crit Care Med 1999, 160:736–755.

    Google Scholar 

  3. Gullapalli D, Phillips LH: Neurologic manifestations of sarcoidosis. Neurol Clin 2002, 20:59–83. This is a review article on neurosarcoidosis.

    Article  PubMed  Google Scholar 

  4. Gullapalli D, Phillips LH: Neurosarcoidosis: pathogenesis, immunology and management. In Inflammatory Disorders of the Nervous System. Edited by Minagar A. Totowa, NJ: Humana Press; 2004:In press

    Google Scholar 

  5. Hills SE, Parkes SA, Baker SB: Epidemiology of sarcoidosis in the Isle of Man-2: evidence for space-time clustering. Thorax 1987, 42:427–430.

    PubMed  CAS  Google Scholar 

  6. Parkes SA, Baker SB, Bourdillon RE, et al.: Epidemiology of sarcoidosis in the Isle of Man-1: a case controlled study. Thorax 1987, 42:420–426.

    PubMed  CAS  Google Scholar 

  7. Panayeas S, Theodorakopoulos P, Bouras A, et al.: Seasonal occurrence of sarcoidosis in Greece. Lancet 1991, 338:510–511.

    Article  PubMed  CAS  Google Scholar 

  8. Vinas FC, Rengachary S: Diagnosis and management of neurosarcoidosis. J Clin Neurosci 2001, 8:505–513.

    Article  PubMed  CAS  Google Scholar 

  9. Du Bois RM, Goh N, McGrath D, et al.: Is there a role for microorganisms in the pathogenesis of sarcoidosis?. J Int Med 2003, 253:4–17. This is an excellent discussion on the available evidence that implicates infectious agents in the pathogenesis of sarcoidosis.

    Article  CAS  Google Scholar 

  10. Baughman RP, Lower EE, du Bois RM: Sarcoidosis. Lancet 2003, 361:1111–1118.

    Article  PubMed  CAS  Google Scholar 

  11. Ziegenhagen MW, Muller-Quernheim J: The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003, 253:18–30. This article discusses immunopathogenesis and the role of cytokines in sarcoidosis.

    Article  PubMed  CAS  Google Scholar 

  12. Muller-Quernheim J: Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998, 12:716–738.

    Article  PubMed  CAS  Google Scholar 

  13. Moller DR: Treatment of sarcoidosis—from a basic science point of view. J Int Med 2003, 253:31–40. This article reviews various current and potential therapies based on the current knowledge of immunopathogenesis of sarcoidosis.

    Article  CAS  Google Scholar 

  14. Pinkston P, Bitterman PB, Crystal RG: Spontaneuous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983, 308:793–800.

    Article  PubMed  CAS  Google Scholar 

  15. Robinson BW, McLemore T, Crystal RG: Gamma-interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985, 75:1488–1495.

    Article  PubMed  CAS  Google Scholar 

  16. Baughman RP, Strohofer SA, Buchsbaum J, et al.: Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990, 115:36–42.

    PubMed  CAS  Google Scholar 

  17. Kreipe H, Radzun HJ, Heidorn K, et al.: Proliferation, macrophage colony-stimulating factor, and macrophage colonystimulating factor-receptor expression of alveolar macrophages in active sarcoidosis. Lab Invest 1990, 62:697–703.

    PubMed  CAS  Google Scholar 

  18. Morris DG, Jasmer RM, Huang L, et al.: Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 2003, 124:929–935. This study emphasizes the need for preservation of CD4+ cells for the development of the granulomatous reaction in sarcoidosis.

    Article  PubMed  Google Scholar 

  19. Muller-Quernheim J, Pfeifer S, Mannel D, et al.: Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992, 145:187–192.

    PubMed  CAS  Google Scholar 

  20. Kim DS, Jeon YG, Shim TS, et al.: The value of interleukin-12 as an active marker of pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2000, 17:271–276.

    PubMed  CAS  Google Scholar 

  21. Ziegenhagen MW, Rothe ME, Schlaak M, et al.: Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003, 21:407–413.

    Article  PubMed  CAS  Google Scholar 

  22. Planck A, Katchar K, Eklund A, et al.: T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20:110–117.

    PubMed  Google Scholar 

  23. Mangiapan G, Hance AJ: Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis 1995, 12:20–37.

    PubMed  CAS  Google Scholar 

  24. Gal AA, Koss MN: The pathology of sarcoidosis. Curr Opion Pulm Med 2002, 8:445–451. This review discusses the histologic features of atypical and rarer pathologic variants of sarcoidosis.

    Article  Google Scholar 

  25. Delaney P: Neurological manifestations in sarcoidosis: review of the literature, with report of 23 cases. Ann Int Med 1977, 87:336–345.

    PubMed  CAS  Google Scholar 

  26. Mirfakhraee M, Crofford MJ, Guinto FC, et al.: Virchow-Robin space: a path of spread in neurosarcoidosis. Radiology 1986, 158:715–720.

    PubMed  CAS  Google Scholar 

  27. Nowak DA, Widenka DC: Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001, 248:363–372.

    Article  PubMed  CAS  Google Scholar 

  28. Stjernberg N, Cajander S, Truedsson H: Muscle involvement in sarcoidosis. Acta Med Scand 1981, 209:213–216.

    Article  PubMed  CAS  Google Scholar 

  29. Krumholz A, Stern BJ: Neurological manifestations of sarcoidosis. In Handbook of Clinical Neurology, Systemic Diseases, Part III. Edited by Aminoff MJ, Goetz R. Amsterdam: Elsevier Science; 1998:463–499.

    Google Scholar 

  30. Chen RC, McLeod JG: Neurological complications of sarcoidosis. Clin Exp Neurol 1989, 26:99–112.

    PubMed  CAS  Google Scholar 

  31. Stern BJ, Krumholz A, Johns C, et al.: Sarcoidosis and its neurological manifestations. Arch Neurol 1985, 42:909–917.

    PubMed  CAS  Google Scholar 

  32. Oksanen V: Neurosarcoidosis: clinical presentation and course in 50 patients. Acta Neurol Scand 1986, 73:283–290.

    Article  PubMed  CAS  Google Scholar 

  33. Chapelon C, Ziza JM, Piette JC, et al.: Neurosarcoidosis: Signs, course and treatment in 35 confirmed cases. Medicine 1990, 69:261–276.

    Article  PubMed  CAS  Google Scholar 

  34. Murialdo G, Tamagno G: Endocrine aspects of neurosarcoidosis. J Endocrin Invest 2002, 25:650–662.

    CAS  Google Scholar 

  35. Caplan L, Corbett J, Goodwin J, et al.: Neuro-ophthalmologic signs in the angiitic form of neurosarcoidosis. Neurology 1983, 33:1130–1135.

    PubMed  CAS  Google Scholar 

  36. Zajicek JP, Scolding NJ, Foster O, et al.: Central nervous system sarcoidosis—diagnosis and management. Q J Med 1999, 92:103–117.

    CAS  Google Scholar 

  37. Hunninghake GW, Gilbert S, Pueringer R, et al.: Outcome of the treatment of sarcoidosis. Am J Resp Care Med 1994, 149:893–898.

    CAS  Google Scholar 

  38. Baughman RP, Lynch JP: Difficult treatment issues in sarcoidosis. J Intern Med 2003, 253:41–45.

    Article  PubMed  CAS  Google Scholar 

  39. Paramothayan S, Jones PW: Corticosteroid therapy in pulmonary sarcoidosis—a systematic review. JAMA 2002, 287:1301–1307. This review analyzes the available evidence on the role of corticosteroids in sarcoidosis.

    Article  PubMed  CAS  Google Scholar 

  40. Reich JM: Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20:227–234.

    PubMed  Google Scholar 

  41. Sharma OP: Neurosarcoidosis. A personal prospective based on the study of 37 patients. Chest 1997, 112:220–228.

    PubMed  CAS  Google Scholar 

  42. Lower EE, Broderick JP, Brott TG, et al.: Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997, 157:1864–1868.

    Article  PubMed  CAS  Google Scholar 

  43. Stern BJ, Schonfeld SA, Sewell C, et al.: The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992, 49:1065–1072.

    PubMed  CAS  Google Scholar 

  44. Agobogu BN, Stern BJ, Sewell C: Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995, 52:875–879.

    Google Scholar 

  45. Menninger MD, Amdur RJ, Marcus RB Jr: Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol 2003, 26:115–118.

    Article  Google Scholar 

  46. Zabel P, Entzian P, Dalhoff K, et al.: Pentoxyfylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997, 155:1665–1669.

    PubMed  CAS  Google Scholar 

  47. Walter MC, Lochmuller H, Schlotter-Weigel B, et al.: Successful treatment of muscle sarcoidosis with thalidomide. Acta Myologica 2003, 22:22–25.

    PubMed  CAS  Google Scholar 

  48. Serio RN: Infliximab treatment of sarcoidosis. Ann Pharmacother 2003, 37:577–581. This article reviews the available evidence on the efficacy of infliximab in the therapy of sarcoidosis.

    Article  PubMed  CAS  Google Scholar 

  49. Pettersen JA, Zochodne DW, Bell RB, et al.: Refractory neurosarcoidosis responding to infliximab. Neurology 2002, 59:1660–1661.

    Article  PubMed  CAS  Google Scholar 

  50. Utz JP, Limper AH, Kalra S, et al.: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177–185.

    Article  PubMed  CAS  Google Scholar 

  51. Kouba DJ, Mimouni D, Rencic A, et al.: Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Derm 2003, 148:147–148.

    Article  CAS  Google Scholar 

  52. Tikoo RK, Kupersmith MJ, Finlay JL: Treatment of refractory neurosarcoidosis with cladribine. N Engl J Med 2004, 350:1798–1799.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Virginia, Box 800394, 22908, Charlottesville, VA, USA

    Lawrence H. Phillips II MD

Authors
  1. Dakshinamurty Ullapalli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence H. Phillips II MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ullapalli, D., Phillips, L.H. Neurosarcoidosis. Curr Neurol Neurosci Rep 4, 441–447 (2004). https://doi.org/10.1007/s11910-004-0066-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0066-9

Keywords

Search

Navigation